157 related articles for article (PubMed ID: 15928917)
1. Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists+.
Bhattacharya P; Leonard JT; Roy K
J Mol Model; 2005 Nov; 11(6):516-24. PubMed ID: 15928917
[TBL] [Abstract][Full Text] [Related]
2. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
3. Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques.
Bhattacharya P; Leonard JT; Roy K
Bioorg Med Chem; 2005 Feb; 13(4):1159-65. PubMed ID: 15670924
[TBL] [Abstract][Full Text] [Related]
4. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
Roy K; Leonard JT
J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
[TBL] [Abstract][Full Text] [Related]
5. QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors.
Borghini A; Pietra D; Domenichelli P; Bianucci AM
Bioorg Med Chem; 2005 Sep; 13(18):5330-7. PubMed ID: 15990318
[TBL] [Abstract][Full Text] [Related]
6. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
Pran Kishore D; Balakumar C; Raghuram Rao A; Roy PP; Roy K
Bioorg Med Chem Lett; 2011 Jan; 21(2):818-23. PubMed ID: 21163647
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.
Jung KY; Kim SK; Gao ZG; Gross AS; Melman N; Jacobson KA; Kim YC
Bioorg Med Chem; 2004 Feb; 12(3):613-23. PubMed ID: 14738972
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on A₃ adenosine receptor antagonists by QSAR tools.
Luan F; Borges F; Cordeiro MN
Curr Top Med Chem; 2012; 12(8):878-94. PubMed ID: 22352915
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists.
Tokarski JS; Hopfinger AJ
J Med Chem; 1994 Oct; 37(21):3639-54. PubMed ID: 7932591
[TBL] [Abstract][Full Text] [Related]
10. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
Roy K; Leonard JT; Sengupta C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
[TBL] [Abstract][Full Text] [Related]
11. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Eur J Med Chem; 2009 May; 44(5):1941-51. PubMed ID: 19110342
[TBL] [Abstract][Full Text] [Related]
12. QSAR of adenosine A3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools.
Bhattacharya P; Roy K
Bioorg Med Chem Lett; 2005 Aug; 15(16):3737-43. PubMed ID: 15993066
[TBL] [Abstract][Full Text] [Related]
13. Affinity prediction on A3 adenosine receptor antagonists: the chemometric approach.
Luan F; Melo A; Borges F; Cordeiro MN
Bioorg Med Chem; 2011 Nov; 19(22):6853-9. PubMed ID: 21992803
[TBL] [Abstract][Full Text] [Related]
14. Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.
Varano F; Catarzi D; Squarcialupi L; Betti M; Vincenzi F; Ravani A; Varani K; Dal Ben D; Thomas A; Volpini R; Colotta V
Eur J Med Chem; 2015; 96():105-21. PubMed ID: 25874336
[TBL] [Abstract][Full Text] [Related]
15. Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.
Saíz-Urra L; Teijeira M; Rivero-Buceta V; Helguera AM; Celeiro M; Terán MC; Besada P; Borges F
Mol Divers; 2016 Feb; 20(1):55-76. PubMed ID: 26205409
[TBL] [Abstract][Full Text] [Related]
16. Predictive QSAR modeling of CCR5 antagonist piperidine derivatives using chemometric tools.
Roy K; Mandal AS
J Enzyme Inhib Med Chem; 2009 Feb; 24(1):205-23. PubMed ID: 18608745
[TBL] [Abstract][Full Text] [Related]
17. Exploring QSARs for binding affinity of azoles with CYP2B and CYP3A enzymes using GFA and G/PLS techniques.
Roy K; Roy PP
Chem Biol Drug Des; 2008 May; 71(5):464-473. PubMed ID: 18373546
[TBL] [Abstract][Full Text] [Related]
18. Novel semi-automated methodology for developing highly predictive QSAR models: application for development of QSAR models for insect repellent amides.
Bhonsle JB; Bhattacharjee AK; Gupta RK
J Mol Model; 2007 Jan; 13(1):179-208. PubMed ID: 17048015
[TBL] [Abstract][Full Text] [Related]
19. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.
Moro S; Bacilieri M; Cacciari B; Bolcato C; Cusan C; Pastorin G; Klotz KN; Spalluto G
Bioorg Med Chem; 2006 Jul; 14(14):4923-32. PubMed ID: 16564691
[TBL] [Abstract][Full Text] [Related]
20. A3 adenosine receptor: homology modeling and 3D-QSAR studies.
Almerico AM; Tutone M; Pantano L; Lauria A
J Mol Graph Model; 2013 May; 42():60-72. PubMed ID: 23567933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
